Valuation: Edesa Biotech, Inc.

Market Cap 7.28Cr 6.38Cr 5.89Cr 5.5Cr 10Cr 688.52Cr 11Cr 71Cr 27Cr 339.67Cr 27Cr 27Cr 1.18TCr P/E 2026 *
-5.22x
P/E 2027 * -4.18x
Enterprise Value 7.28Cr 6.38Cr 5.89Cr 5.5Cr 10Cr 688.52Cr 11Cr 71Cr 27Cr 339.67Cr 27Cr 27Cr 1.18TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
79.78%
Yield 2026 *
-
Yield 2027 * -
1 day-7.69%
1 week+12.48%
Current month+6.09%
1 month+6.09%
3 months+43.71%
6 months+417.57%
Current year+439.44%
1 week 6.6
Extreme 6.6
8.46
1 month 4.56
Extreme 4.56
8.46
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2015
Director of Finance/CFO 57 01/05/2025
President 48 07/06/2019
Director TitleAgeSince
Chairman 50 07/06/2019
Director/Board Member 55 07/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap.
16/06Free

Founder

1,53,550 1.7268%
16/06Sell

Founder

1,53,530 1.7266%
01/06Free

Founder

1,671 0.0188%
Change 5-day change 1-year change 3-year change Capi.($)
-6.47%+12.48%+277.34%+42.06% 7.28Cr
+0.13%-1.33%+67.18%+121.93% 5.56TCr
+6.76%+22.83%+91.66%+101.42% 5.22TCr
+2.08%+3.08%-12.68%-13.11% 2.31TCr
+0.84%+5.43%+3.30%+411.61% 2.24TCr
+6.78%+14.47%+40.28%-6.67% 1.73TCr
+0.97%+3.81%+30.68%-32.21% 1.59TCr
-0.40%+6.35%+23.90%+188.03% 1.38TCr
+9.96%+19.81%+157.65%+320.70% 1.35TCr
+4.21%+4.76%+33.21% - 1.24TCr
Average +2.36%+7.30%+71.25%+125.97% 2.26TCr
Weighted average by Cap. +3.27%+7.62%+54.69%+127.54%

Financials

2026 *2027 *
Net sales - -
Net income -1.35Cr -1.18Cr -1.09Cr -1.02Cr -1.92Cr -127.63Cr -1.96Cr -13Cr -5.07Cr -63Cr -5.07Cr -4.96Cr -218.61Cr -2.68Cr -2.34Cr -2.16Cr -2.02Cr -3.8Cr -252.91Cr -3.89Cr -26Cr -10Cr -124.77Cr -10Cr -9.83Cr -433.18Cr
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
17
Date Price Change Volume
29/26/29 $7.660 -6.47% 53,254
26/26/26 $8.190 +9.64% 67,949
25/26/25 $7.470 -6.04% 1,30,275
24/26/24 $7.950 +4.06% 1,26,740
23/26/23 $7.640 +12.19% 1,23,276
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
8.190USD
Average target price
14.00USD
Spread / Average Target
+70.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock